» Articles » PMID: 21273492

The Possible Protective Role of Glucagon-like Peptide 1 on Endothelium During the Meal and Evidence for an "endothelial Resistance" to Glucagon-like Peptide 1 in Diabetes

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2011 Jan 29
PMID 21273492
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion. However, GLP-1 also improves endothelial function in diabetes.

Research Design And Methods: Sixteen type 2 diabetic patients and 12 control subjects received a meal, an oral glucose tolerance test (OGTT), and two hyperglycemic clamps, with or without GLP-1. The clamps were repeated in diabetic patients after 2 months of strict glycemic control.

Results: During the meal, glycemia, nitrotyrosine, and plasma 8-iso prostaglandin F2α (8-iso-PGF2a) remained unchanged in the control subjects, whereas they increased in diabetic patients. Flow-mediated vasodilation (FMD) decreased in diabetes, whereas GLP-1 increased in both groups. During the OGTT, an increase in glycemia, nitrotyrosine, and 8-iso-PGF2a and a decrease in FMD were observed at 1 h in the control subjects and at 1 and 2 h in the diabetic patients. In the same way, GLP-1 increased in both groups at the same levels of the meal. During the clamps, in both the control subjects and the diabetic patients, a significant increase in nitrotyrosine and 8-iso-PGF2a and a decrease in FMD were observed, effects that were significantly reduced by GLP-1. After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects.

Conclusions: Our data suggest that during the meal GLP-1 can simultaneously exert an incretin effect on insulin secretion and a protective effect on endothelial function, reasonably controlling oxidative stress generation. The ability of GLP-1 in protecting endothelial function seems to depend on the level of glycemia, a phenomenon already described for insulin secretion.

Citing Articles

Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.

Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S Front Cardiovasc Med. 2025; 11:1446468.

PMID: 39741663 PMC: 11685754. DOI: 10.3389/fcvm.2024.1446468.


Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide.

Taktaz F, Fontanella R, Scisciola L, Pesapane A, Basilicata M, Ghosh P Cardiovasc Diabetol. 2024; 23(1):242.

PMID: 38987789 PMC: 11238498. DOI: 10.1186/s12933-024-02319-7.


Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.

Akbari A, Hadizadeh S, Heidary L J Diabetes Res. 2024; 2024:3212795.

PMID: 38529046 PMC: 10963118. DOI: 10.1155/2024/3212795.


Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake.

Hamamah S, Amin A, Al-Kassir A, Chuang J, Covasa M Nutrients. 2023; 15(15).

PMID: 37571301 PMC: 10421457. DOI: 10.3390/nu15153365.


Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.

Inceu A, Neag M, Craciun A, Buzoianu A Int J Mol Sci. 2023; 24(4).

PMID: 36834796 PMC: 9965280. DOI: 10.3390/ijms24043385.


References
1.
Hojberg P, Vilsboll T, Zander M, Knop F, Krarup T, Volund A . Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med. 2008; 25(11):1268-75. DOI: 10.1111/j.1464-5491.2008.02579.x. View

2.
Nauck M, Heimesaat M, Orskov C, Holst J, Ebert R, Creutzfeldt W . Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1):301-7. PMC: 330027. DOI: 10.1172/JCI116186. View

3.
Campia U, Sullivan G, Bryant M, Waclawiw M, Quon M, Panza J . Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol. 2003; 286(1):H76-82. DOI: 10.1152/ajpheart.00539.2003. View

4.
Oeseburg H, de Boer R, Buikema H, van der Harst P, van Gilst W, Sillje H . Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010; 30(7):1407-14. DOI: 10.1161/ATVBAHA.110.206425. View

5.
Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L . Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001; 44(7):834-8. DOI: 10.1007/s001250100529. View